Xeljanz XR 11 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FV7M1
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,400
Award facts
- Contract value 100% obligated
- $11,400.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11.4K to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on January 8, 2026, with an ultimate completion date of January 9, 2026. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract and is performed at the awardee's facility in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $1 billion through December 2026, which serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major pharmaceutical distributor and critical vendor for federal medical procurement. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of pharmaceutical products across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical devices to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for XELJANZ XR, a rheumatoid arthritis treatment, exemplifies the company's role in supporting military and federal healthcare operations through the DLA's Medical Supply Chain.
Quick answers
Who was awarded contract SPE2DR26FV7M1?
SPE2DR26FV7M1 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FV7M1 worth?
The government has obligated $11,400 on SPE2DR26FV7M1.
Is contract SPE2DR26FV7M1 an order under another contract?
Yes. SPE2DR26FV7M1 is a delivery order under SPE2DR25D2214, an indefinite delivery contract.
Was contract SPE2DR26FV7M1 competed?
The extent of competition for SPE2DR26FV7M1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award